Guo Guangchang

Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa

Retrieved on: 
Thursday, July 15, 2021
Companies of China, Companies, Economy of China, Fosun International, H shares, Fosun Pharma, Sun Pharma, Guo Guangchang

Kintor and Fosun Pharma Development will collaborate on the emergency use authorization applications, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.

Key Points: 
  • Kintor and Fosun Pharma Development will collaborate on the emergency use authorization applications, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.
  • According to the licensing agreement, Fosun Pharma Development will be granted exclusive rights of registration and commercialisation of proxalutamide in the Collaboration Regions.
  • Shanghai Fosun Pharmaceutical Development Ltd. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma Group";stock code: 600196.SH, 02196.HK) is a leading global pharmaceutical and healthcare provider in China.

Fosun Continues Joining Hand with Other Benevolent Enterprises in Donating Medical Supplies, to Hospitals in the U.S.

Retrieved on: 
Wednesday, April 1, 2020
Companies of China, Economy of China, Animal virology, Coronavirus, Guo Guangchang, Fosun International, Companies

In response to the increasing numbers of global coronavirus pneumonia patients, Fosun's "Global Anti-Virus Relief Scheme" is continuing its efforts.

Key Points: 
  • In response to the increasing numbers of global coronavirus pneumonia patients, Fosun's "Global Anti-Virus Relief Scheme" is continuing its efforts.
  • The total donated materials include 69,700 masks and 2,300 medical suits.
  • Together we keep calm, unite to fight, and carry on," said Fosun International's Chairman Guo Guangchang.
  • This is Fosun's first batch of medical protection supplies to the US since Fosun has kicked off its second phase of operations against the coronavirus.

BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China

Retrieved on: 
Monday, March 16, 2020
Companies of China, Companies, Fosun International, Economy of China, H shares, Fosun Pharmaceutical, Pharmaceutical industry, Guo Guangchang

If approved, Fosun Pharma will commercialize the vaccine in China.

Key Points: 
  • If approved, Fosun Pharma will commercialize the vaccine in China.
  • BioNTech will supply the mRNA vaccine for clinical trials from GMP manufacturing facilities in Europe along with its partner Polymun .
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma, Stock Symbol: 600196.SH, 02196.HK) is a leading healthcare group founded in China.
  • These forward-looking statements may include, but may not be limited to, the ability of BioNTech and Fosun Pharma to develop and commercialize a vaccine for COVID-19; the potential for a broader collaboration between BioNTech and Fosun Pharma; and the ability to consummate an equity investment by Fosun Pharma in BioNTech.